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Strategies to manage COPO
Learning objectives
After reading this article, the reader should be able
to:
• Understand the range of ma nagement stra tegies
availab le for COPO; and
• Discuss the evidence behind curren t COPD
management strategies, and be confident In
making recommendations to patients and GPs.
Case study
Mrs AJ, a 59-year-old female, comes into the pharmacy
with a prescription for tiotrop ium iSoirivs), She says she
has never used it before, and her doctor prescribed it
for her worsening shortness of breath and coughing fits.
When asked, she says she started smoking when in her
20s, and still smokes 10 to 15 cigarettes per day. Her
doctor told her she should seriously consider quitt ing,
but she is hesitant, particularly when her husband also
smokes. She asks if ther e is anything else that she can
do to improve her symptoms.
..
MISAJ, a 59-year-a.'d female, comas into the pllBmJaCY w,'lh a prescription
for tiotrop,'um ISplfiva).
of this article is to review the evidence for the strategies
used to optimally manage COPD, as outlined in the COPD-X
Guidelines.
Introduction
Chronic obstructive pu lmonary disease {COPD} is a major
ca use of disability, hospital admission and premature
death in Australia. More than half a mill ion Austra lians are
estimated to have CO PD , and the prevalence is likely to
escalate as the popula tion ages. Despite COPD being less
preva lent in the population than asthma, it is responsible for
many more deaths. With about 5,400 deaths attributed to
it in 2003. COPD ran ks fourth among the common causes of
death in Austra lia." Furthermore, capo is associated with a
significant level of disability in abou 34% of su fferers, rising
to 68% in those aged 65 years and over.' In recognition of
the enormo us burden that capo places on the Australian
community, the Australian Lung Foundation and Thoracic
Society of Australia and New Zea land recently developed
clinical practice guidelines to improve the diagnosis and
managementof capo.TheCOPD-X guidelines, as summarised
in Table 1, aim to effect changes in clinical practice based on
sound evidence, and sh ift the emphasis from a predominant
reliance on pharmacolog ical treatment of COPOto a ra nge of
interventions including patient education, sel f-management
of exacerbations and pu lmonary reha bilitation.' The focus
Smoking cessation
While there is evidence from epidemiological studies that
non-smokers can develop chron ic airflow obstruction."
tobacco smoke remains the most important ca use of capo
worldwide, with up to 50% of smokers noted to develop
the condit ion.' The forced expiratory volume in one second
(FEV1) dec lines at about 45mLlyear in smokers , compa red to
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Table 1. Summary of the COPD-X quidelines'
*NHMRCleve lsof evidence:
I Evidenceobtained froma systematic reviewof all relevant randomisedcontrolled trials.
II Evidence obtained from at least one properlydesigned randomised controlled trial.
There is good evidence that health professionals can
substantially increase quitt ing and read iness to qu it in the
population. Even a brief (3-minute) period of counselling to
urge a smoker to quit resu lts in smoking cessation rates of
5-10%.11 Furthermore, co llaborative efforts among health
professionals are more effective than interventions by on ly
one type of health profess ional; a recent US Tobacco Survey
of 1)23 smokers found that being asked about smoking by
two or more types of professionals substantially increased
the odds of recent quitt ing (odds ratio [OR] = 2.37; 950.'
confidence interval [Gil = 1.15 to 4.881. Moreover, it is
imperative that smoking cessation interventions involve
C: Confirm diagnosis and assess severity Evidence leve l'"
• Smoking is the most important risk factor for CGPO I
• Consider COPO in patientswith other smoking-related diseases I
• Consider COPO inall smokers and ex-smokers older than35 years II
• The diagnosisof COPOrests on the demonstra tion of airflow limitation which is not fully reversible II
0: Optimisefunction Evidence level*
• Inhaled bronchodilators provide symptomrelief in patientswith CG PO and may increase exercise capacity I
• l ong-acting bronchodilators provide sustained relief of symptoms in moderate to severe CGPo I
• l ong termuse of oral corticosteroids is not recommended I
• Inhaled corticosteroids should be cons idered in patients with a documented response or those who have II
severe CO PO with frequent exacerbations
• Pulmonary rehabilitation reducesdyspnoea. anxiety and depress ion, improves exercise ca pacity and quality I
of lifeand may reduce hospitalisation
P: Prevent deterioration Evidence leve l*
• Smokingcessation reduces the ra te of decline of lung function I
• General practitioners and pharmacistscan help smokers quit I
• Treatment of nicotine dependence is effectiveand should be offered to smokers I
• Pharmacotherapies double the success of quit attempts; behavioural techniques further increase the quit I
rateby up to 50%
• Influenzavaccination reduces the risk of exacerbations, hospitalisa tion and death I
• Inhaled corticosteroids are indicated for patients with adocumented response orwho have severe CGPO II
with frequent exacerbations
• Mucolytics may reduce the frequency and duration of exacerbations I
D: Develop a support network and self-management plan Evidence leve l"
• Pulmonary rehabi litation increases patient/carer knowledge base. reducescarer strainand develops posit ive I
attitudes towards self-management-and exercise
• Multidisciplinarycare plans and individual self-management plansmay help to prevent or manage crises II
X: Manage eXacerbations Evidence level*
• Inhaled bronchodilators areeffective treatmentsfor acute exacerba tions I
• Oral corticosteroids reduce the severity of and shorten recovery fromacute exacerbations I
• Exacerbations withclinica l signs of infection benefit fromantibiotic therapy II
• Multidisciplinary care may assisthome management II
the decline assoc iated with normal ageing of approximately
30mL/year in non-smokers."
Smoking cessation is the single most effective - and cost
effective- intervention to reduce the risk of developing COPD
and stop its proqress ion." While smoking cessation may lead
to minimal improvements in lung funct ion, more importantly
I it will slow the rate of decline and delay the onset of
disablement. Smoking cessation has been shown to reduce
I
the rate of decline of FEV1 to approximately that of never-
smokers (Figure 11. It has also been demonstrated that the
I slowed decline in FEV, is sustainedyears after quitting ."
'f- ----""
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The COFD-XGuIdelines state that 'inr.afed bronchodiJatorsprovide symptom
relief in pationts with COPOand may increase excrcis« capacity'.
combinations of psychological and social support mechanisms,
and pharmacothe rapy."
Self-management plans
Self-management interventions improve various outcomes
for many chron ic condit ions , Re sea rch in self-management
plans for capo is relatively new, and variable results have
been reported in the literature. A Canadian multicentre
randomised controlled trial (RCT) involving 191 patients
from seven hospitals evaluated an intervention consisting
of a comprehensive patient education program administered
through weekly visits by trained hea lth professionals over a
two-month period with monthly telephone follow-up." After
12 months, hospital admissions for exacerbation of capo
were reduced by 40% in the intervention group compared
to the usual care group (P < 0,05), and admissions for other
health problems were red uced by 57% [P< 0.05). Emergency
department visits were reduced by 41 % (P < 0.05) and
unscheduledphysicianvisits by59% (P < 0.01 ).
In contrast, a New Zealand RCT of structured one-hour
education sessions on the use of a written self-management
plan and patient-init iated short courses of antibiotics and
oral cort icosteroids failed to show any added health benefit,
in terms of health util isation, or self-reported outcomes,
compared to usua l cars." A recent systematic review on
self-managem ent educa tion in capo could not draw any
conclusions about the effectiveness of self-management
beca use of the large variation of outcome measures used in
a limited number of included studies, and noted the evident
need for additional large RCTs featuring long-term follow-up,
before more conclusions can bedrawn."
Pulmonary rehabilitation
Pulmonary rehabilitation programs involve patient
assessment. exercise training, nutrit ional intervention and
psychosocial support, and are designed to reduce symptoms,
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optimise functional status, increase participation and reduce
health care costs through stabilising or reversing systemic
man ifestations of capo.IS The components of pulmonary
rehabil itation are shown in Tab le 2,
Table 2. Components of comprehensive
pu lmonary re habilitation programs 17
1. Education, includingself-management strategies
2. Upper and lower extremity exercise training, resistance
training
3. Psychosocial support, when indicated
4, Encouragement of activity and exercise in the home
setting
5. Outcome assessment
6. Promotion of long-term adherence.
Although pu lmonary rehabi litation has not been shown to have
a substantial effect on the specific respiratory impairment
in COPD,IO a large body of scientific evidence demonstrates
its beneficial effects over multiple' outcome areas. A
recen t systematic review including 31 RCTs of pulmonary
rehabilitation for capo on disease-spec ific health status was
conducted, Th is review reported that in four important qua lity
of life domains (Chronic Respiratory Questionna ire scores
for Dyspnoea. Fat igue, Emotional Function and Mastery).
the effect was larger than the minimal clinically important
difference of 0.5 units." The authors concluded that the
improvements for all outcomes were moderately large and
clinica lly significant. and that the results strong ly support
pulmonary rehabilitation as part of the spectrum of the
management of pa tients with capo.
Pharmacological therapy
Inhaled bronchodilators
The CO PD-X Guidelines state that 'inhaled bronchod ilators
prov ide sym ptom relief in patients with capo and may
increase exerc ise capacitv'.' The inhaled bronchodilators
include short- and long-acting bete-Z-aqonists (LABAs), and
short- and long-acting anticholinergics. Systematic reviews
comparing the efficacy of salbutamol and ipratropium found
nomajor differences between the responses to either drug or
the combination for the treatment of acute exacerba tions of
COPD20 or stable COPD.11
A recent systematic review of RCTs comparing tiotropium to
other bronchodilators used in patients with stable capofound
that tiotropium reduced the odds of a capoexacerbation (OR
0.74; 95% CI 0,66 to 0.83) and related hospitalisations (OR
0,64; 95% CI 0.51 to 0.82) compared to placebo or ipratropi um.
Reductions in these endpo ints compared to LABAs were not
statistically siqnitlcant."
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Current evidoncc does not support long-term antibiotic use to prevent
exacertxltions in patients with COPO,
A recent report from the manufacturer of Spitive. Boehringer
Ingelheim. to the United States Food and Drug Admin istration
(FDA) raised alarms abo ut a possible increased risk of
stroke in patients using tiotrop ium. Pooled analysis from 29
placebo controlled clinical studies estimated that the risk of
stroke was eight per 1000 patients treated for one yea r with
tiotroplurn . and six per 1000 patients treated for one year
with placebo." The FDA warned that these pre liminary results
should be interpreted with ca ution . as while the ana lysis
provid es early information about potential safety issu es, it
has inherent limitations and furthe r investigation using other
data sources is requ ired . The FDA will annou nce conclusions
and recommendation s to the public later this yea r after data
froma four-year studyhave been rec eived and ana lysed.
Corticosteroids
Inhaled corticosteroids (ICS) have proven benefit in the
treatment of airway inf lammation in asthma, but.their role in
CO PD has been the subject of much controversy. A systematic
review of 47 RCTs found that long-term use of ICS (>6 months)
did not significantly reduce the rate of dec line in FEV, or
mortality in COPO patients. However, long-term use of ICS
reduced the mean rate of exacerbations and slowed the rate
of dec line in quality of life. as measured by the St. George's
Re sp ira tory Questionnaire. The authors concluded that
patients and health profess iona ls should balancethe potential
benefits of ICS(reduced rate of exacerbations, slowed decline
in qual ity of life) against the adverse effects (oral thrush,
'hoarseness and unknown long-term side effects]."
A recent study compared the relative efficacy of salmetero ll
flutica sone 50/500~ g twice -da ily and tiotropium 1 8~ g once-
dai ly in preventing exacerbations and related outco mes over
two years in severe and very severe COPO.2; Interestingly.
the study showed no difference in reduction of exacerbations
between the treatment groups, although patients rece iving the
sa lmeterol/ fluticasone combination had better health status
as measured by the St George's Respi ratory Questionna ire
IP<0.01) and had better survival (all-cau se mortality rate 3%
versus 6% with tiotropium, P< 0.05). This was the first study
to directly co mpare an ICS/LABA comb ination and a long-
acting anticholine rg ic, and has important implications for the
cho ice of therapy in the management of seve re COPD .
Th e long-term use of oral corticosteroids for COPD is not
recommended.' Systematic rev iew found that long-term use
did not slow the decline in lung function, and increased the
risk of side effects such as diabetes and osteoporos is."
However. there was some evidence that high doses (::: 30mg
prednisolone/day) improved FEV, ove r a sho rt period (weighted
mean difference 53mL; 95% CI 22 to 84mL. after two weeks
treatment).
Methylxanthines
Th ere is evidence that theophylline improves FEV\ (weighted
mean difference 100mL; 95% CI 40 to 60mL) and arterial
blood gas tensions (Pa02: weighted mean difference 3.2mm
Hg; 95% CI 1.2 to 5.1 , and PaC0 1: weighted mean difference
-2.4mm Hg; 95% CI -3.5 to -1 .2) compared to place bo 27
However. methylxanthines are rarely used becau se of their
narrow therapeutic indexand potential for significant adve rse
effects and drug interactions. With close mon itoring of
individual pat ients and their serum drug levels, it appea rs
that beneficial effects may be obtained in COPD patients who
remain symptomatic despite first-line bron chodilator therapy.
Antibiotics
Current evidence does not support long-term antibiotic use
to prevent exacerbat ions in patients with COPD. Systematic
review found that prophylactic antibiotics in chronic
bronchitis/Cfll'D had a sma ll but statistically significant
effect in reducing the days of illness due to exacerbations."
However, they do not have a place in routine treatment
because of concerns about the deve lopment of antibiotic
resistance and the possibility of adve rse effects.
A systematic review of the va lue of antibiotics in ac ute
COPD exacerbations found that their use. regardless of
choice. reduced the risk of short-term mortality by 77 %,
decreased the risk of treatment failure by 53 % and the risk
of sputum purulence by 44%; with a sma ll increase in the
risk of diarrhoea." Antibiotics are therefore recommended for
exacerbations with an increase in cough. dyspn oea, sputum
vo lume or puru lence.
Vaccinations
The COPD-X Guidel ines recomm end that all patients with
moderate to severe CO PD should receive annua l influenza
vaccinations.' Data from RCTs demonstrate that administration
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of an inactivated influenza vaccine to COPO patients
sign ificantly reduces exacerbations."
Pn eumococcal vacci nation is known to be highly effective in
preventing invasive bacteraemic pneumococcal pneumon ia,
but may be less effective in elderly or immunocompromised
patients. There is no direct evidence of its efficacy in
preventing pneumococca l exacerbations of COPO,JI but the
prevention of pneumonia in these patients with already
reduced respiratory reserve is a worthy goal in its own riqht.'
Mucolytics
A systematic review reported a 20% reduction in the number
of exacerbations per patien t with oral mucolyt ics compared
to placebo." However, no differences in lung fun ction or in
adverse effects between the treatments were reported .
Bearing in mind that significant quality of life and health care
costs result from COPO exacerbations, health profess ionals
and patients need to judge whether the reduction in
exacerbation rate is large enough to warrant daily treatment
with these medicines. Benefit may be greater in individua ls
who have frequent or prolonged exacerbations, or those who
are repeatedly admitted to hospital with COPO, although
data from RCTs is not presently avai lable to support this
recommendation. "
Case study
Yo u dispense the tiotropium prescription for Mrs AJ,
supply her with the appropriate inhalat ion device, and
counsel her on its use. Kn owing that collaborative
efforts among health professionals are more effect ive
than smoking cessation interventions by only one type
of health professional, you reinforce what her doctor
told her about the benefits of smoking cessation (for
both her and her husband) and recommend nicotine
replacement therapy. Yo u also give her the Pharmacy
Self Ca re Fact Cards on Smoking, Nicotine Rep lacement
Therapy, and Staying a Non-Smoker. You determine
that she will be receiving influenza and pneumococcal
vaccines in several weeks. In addition, you tell her that
there is extensive evidence for pulmonary rehabilitation
programs in improving wellbeing and quality of life, and
refer her to a local rehabilitation program."
'TheAustralian Lung Foundation maintains a comprehensive national
databaseofprogramsand can supply contact details for programs
Australia-wide. Patients can enteraprogram either byasking for a
referal from their GPand/or respiratoryspecialist. Many programs will
also accept patients who contact them directly. Go to: www.lungnet.
org.au/copd/p,-pulmonJehab.i1tml orcall 7800 654 301 formore
information.
Su bmit your answers online at www.psa.org.au and receive
automatic feedback, /
Bonnie Bereznicki, Dr Luke Bereznicki and Professor Gregory Peterson,
Unit forMedication Outcomes Researchand Education, School of
Pharmacy, University ofTasmania.
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